AN2 Therapeutics, Inc. (ANTX) Misses Q1 EPS by 10c

AN2 Therapeutics, Inc. (NASDAQ: ANTX) reported Q1 EPS of ($0.35), $0.10 worse than the analyst estimate of ($0.25).

For earnings history and earnings-related data on AN2 Therapeutics, Inc. (ANTX) click here.

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• Lument Finance Trust (LFT) Misses Q2 EPS by 17c
• LogicBio Therapeutics (LOGC) Misses Q2 EPS by 10c